سعر مونتيلوساب 5مجم 7 اقراص مضغ 2026

Montelukast 5 mg chewable tablets, box of 7 (Montelosab, Sabaa). Paediatric-strength chewable leukotriene receptor antagonist for asthma.

• Add-on therapy in mild to moderate persistent asthma inadequately controlled on inhaled corticosteroids and as-needed short-acting beta-agonists; prophylaxis of exercise-induced bronchoconstriction. Also symptomatic relief of seasonal allergic rhinitis when indicated for asthma.Population: Children 6 to 14 years with asthmaMedicines.org.uk (eMC / MHRA)

• Common: headache, abdominal pain (paediatric studies); also diarrhoea, nausea, vomiting, rash, pyrexia, elevated transaminases. Post-marketing: neuropsychiatric events, hypersensitivity including anaphylaxis, Churg-Strauss syndrome (very rare).International label, same formulation · Medicines.org.uk (eMC / MHRA)

• Hypersensitivity to montelukast or to any of the excipients.International label, same formulation · Medicines.org.uk (eMC / MHRA)

• Not for acute asthma attacks; keep rescue short-acting inhaled beta-agonist available. Do not abruptly substitute for inhaled/oral corticosteroids. Alert for neuropsychiatric events (behavioural changes, depression, suicidality); discontinue if they occur. Rare Churg-Strauss-like eosinophilic vasculitis reported with anti-asthma agents including montelukast.International label, same formulation · Medicines.org.uk (eMC / MHRA)

• CYP inducers (phenobarbital, phenytoin, rifampicin)Phenobarbital reduced montelukast AUC ~40%; caution with CYP3A4/2C8/2C9 inducers. Gemfibrozil increased exposure ~4.4-fold; no routine dose adjustment but monitor adverse reactions.Medicines.org.uk (eMC / MHRA)

• May be used during pregnancy only if clearly essential. Published cohort data have not established a drug-associated risk of major birth defects; animal studies do not indicate harmful reproductive effects.International label, same formulation · Medicines.org.uk (eMC / MHRA)
• Unknown whether montelukast is excreted in human milk; may be used in breast-feeding only if clearly essential.International label, same formulation · Medicines.org.uk (eMC / MHRA)

• Montelukast: Orally active, selective antagonist of the cysteinyl leukotriene type-1 (CysLT1) receptor, blocking LTD4-mediated airway oedema, smooth-muscle contraction and inflammation (SINGULAIR US label).